Clinical meaning
Bacteria develop antibiotic resistance through four major mechanisms. Enzymatic inactivation is the most clinically significant — beta-lactamases hydrolyze the beta-lactam ring rendering penicillins and cephalosporins ineffective; extended-spectrum beta-lactamases (ESBLs) additionally hydrolyze third-generation cephalosporins, while carbapenemases (KPC, NDM, OXA-48) inactivate carbapenems, the last-resort beta-lactams. Efflux pumps actively transport antibiotics out of the bacterial cell before they reach their target, conferring resistance to tetracyclines, fluoroquinolones, and macrolides. Target site modification alters the antibiotic binding site — MRSA produces an altered PBP2a (encoded by mecA gene) with low affinity for all beta-lactams, and VRE modifies the D-Ala-D-Ala peptidoglycan terminus to D-Ala-D-Lac, preventing vancomycin binding. Decreased permeability through porin channel mutations in gram-negative outer membranes restricts antibiotic entry, contributing to Pseudomonas and Acinetobacter resistance. Resistance genes spread horizontally via plasmids, transposons, and conjugation, enabling rapid dissemination across bacterial species.